Study seeks best heart check schedule for breast cancer drug

NCT ID NCT02696707

Completed Knowledge-focused Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 200 women with early-stage HER2-positive breast cancer who were taking trastuzumab. The goal was to compare two standard schedules for monitoring heart function: every 3 months versus every 4 months. Researchers wanted to see if less frequent monitoring could be safe and effective, since trastuzumab can sometimes cause heart damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors choose the safest and most efficient heart monitoring schedule for breast cancer patients on trastuzumab.
What could go wrong: This is a small, completed study comparing existing standard-of-care schedules, not testing a new treatment. Results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Cardiotoxicity HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Southlake Regional Health Centre

Newmarket, Ontario, L3Y 2P9, Canada
The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada
The Ottawa Hospital Cancer Centre

Ottawa, Ontario, K2H 8L6, Canada
Thunder Bay Regional Health Sciences Centre

Thunder Bay, Ontario, P7B 6V4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.